Table 2.
Clinical characteristics of men with favorable risk PCa in OBS vs IMT cohorts
| OBS | IMT | |||||
|---|---|---|---|---|---|---|
| (n = 362) | (n = 1063) | |||||
| N | % | N | % | p-value | Standardized difference a | |
| Comorbid Indices (CCI) | ||||||
| 0 | 225 | 62.2% | 750 | 70.6% | <.01 | 17.83 |
| 1 | 59 | 16.3% | 183 | 17.2% | 0.69 | 2.45 |
| 2+ | 78 | 21.6% | 130 | 12.2% | <.01 | 25.04 |
| Comorbid Conditions | ||||||
| Hypertension | 153 | 42.3% | 405 | 38.1% | 0.16 | 8.50 |
| Diabetes | 61 | 16.9% | 134 | 12.6% | 0.04 | 11.99 |
| COPD | 43 | 11.9% | 82 | 7.7% | 0.02 | 14.03 |
| Congestive Heart Failure | 13 | 3.6% | 27 | 2.5% | 0.30 | 6.09 |
| Dementia | 0 | 0.0% | 3 | 0.3% | 0.31 | 7.52 |
| Benign Prostatic Hyperplasia | 130 | 35.9% | 388 | 36.5% | 0.84 | 1.22 |
| Body Mass Index | ||||||
| Underweight (< 18.5) | 1 | 0.3% | 5 | 0.5% | 0.62 | 3.18 |
| Normal (18.5–24.9) | 42 | 11.6% | 102 | 9.6% | 0.27 | 6.52 |
| Overweight (25.0–29.9) | 118 | 32.6% | 342 | 32.2% | 0.88 | 0.90 |
| Obese (≥30) | 112 | 30.9% | 336 | 31.6% | 0.81 | 1.44 |
| Unknown | 89 | 24.6% | 278 | 26.2% | 0.56 | 3.60 |
| Family History of Prostate Cancer | ||||||
| Yes | 74 | 20.4% | 262 | 24.7% | 0.10 | 10.07 |
| No | 208 | 57.5% | 598 | 56.3% | 0.69 | 2.43 |
| Unknown | 80 | 22.1% | 203 | 19.1% | 0.22 | 7.42 |
| Family History of Cancer | 109 | 30.1% | 339 | 31.9% | 0.53 | 3.85 |
| Prostate Cancer Characteristics | ||||||
| Index PSA (Mean, SD) | 5.8 | 2.5 | 5.7 | 2.5 | 0.31 | 6.31 |
| < 4 ng/mL | 69 | 19.1% | 208 | 19.6% | 0.83 | 1.28 |
| 4–10 ng/mL | 256 | 70.7% | 758 | 71.3% | 0.83 | 1.30 |
| > 10 ng/mL | 30 | 8.3% | 77 | 7.2% | 0.52 | 3.90 |
| Unknown | 7 | 1.9% | 20 | 1.9% | 0.95 | 0.38 |
| Index Clinical Stage b | ||||||
| Stage 1 | 303 | 83.7% | 855 | 80.4% | 0.17 | 8.52 |
| Stage 2 | 55 | 15.2% | 184 | 17.3% | 0.35 | 5.73 |
| Unknown | 4 | 1.1% | 24 | 2.3% | 0.17 | 8.97 |
| Index Total Gleason Score = 3 + 4 | 83 | 22.9% | 377 | 35.5% | <.01 | 27.82 |
| Risk Category c | ||||||
| Low-risk | 236 | 65.2% | 585 | 55.0% | <.01 | 20.84 |
| Intermediate-risk | 117 | 32.3% | 461 | 43.4% | <.01 | 22.91 |
| Unknown | 9 | 2.5% | 17 | 1.6% | 0.28 | 6.27 |
OBS observation, IMT immediate treatment, SD standard deviation, COPD chronic obstructive pulmonary disease
aSD = standardized difference (SD is defined as the difference in sample means or proportions divided by standard error; reported as 100*|actual standardize difference|. Standardize differences >|10| are considered significant
bClinical stage: anatomic Extent of the disease based on the clinical T, N and M element
cRisk Categories: Low risk (T1-T2A, PSA level ≤ 10 ng/mL, and Gleason score ≤ 6) and intermediate-risk (T1 or T2, PSA level > 10 and ≤ 20 ng/mL, and Gleason score = 7)